NKTR vs. BRK-B

In the year-to-date period, NKTR achieves a -16.66% return, which is significantly lower than BRK-B's 17.14% return. Over the past 10 years, NKTR has underperformed BRK-B with an annualized return of -22.25%, while BRK-B has yielded a comparatively higher 14.21% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NKTR Sharpe Ratio is -0.55, which is lower than the BRK-B Sharpe Ratio of 1.58. The chart below compares the historical Sharpe Ratios of NKTR and BRK-B, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NKTR nor BRK-B has paid dividends to shareholders.

The maximum NKTR drawdown since its inception was -99.61%, which is greater than BRK-B's maximum drawdown of -53.86%. Use the drawdown chart below to compare losses from any high point for NKTR and BRK-B. For additional features, visit the drawdowns tool.

Nektar Therapeutics (NKTR) has a higher volatility of 34.56% compared to Berkshire Hathaway Inc. (BRK-B) at 10.99%. This indicates that NKTR's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Nektar Therapeutics and Berkshire Hathaway Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.